Nj State Employees Deferred Compensation Plan Alnylam Pharmaceuticals, Inc. Transaction History

Nj State Employees Deferred Compensation Plan

$824 Million
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2024 Aug 06, 2024	BUY	$143.31 - $247.0 $143,310 - $247,000	1,000 New	1,000 $243,000
Q3 2022 Oct 28, 2022	BUY	$138.54 - $232.0 $138,540 - $232,000	1,000 New	1,000 $200,000

Others Institutions Holding ALNY

# of Institutions

644

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

Capital World Investors Los Angeles, CA

16.5M
Shares

$4.19 Billion
0.73% of portfolio
Vanguard Group Inc Valley Forge, PA

12.6M
Shares

$3.21 Billion
0.06% of portfolio
Black Rock Inc. New York, NY

9.55M
Shares

$2.42 Billion
0.05% of portfolio
Capital Research Global Investors Los Angeles, CA

5.24M
Shares

$1.33 Billion
0.31% of portfolio
Wellington Management Group LLP Boston, MA

4.95M
Shares

$1.26 Billion
0.24% of portfolio

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nj State Employees Deferred Compensation Plan, based on Form 13F filings with the SEC.

News

Stay updated on Nj State Employees Deferred Compensation Plan with notifications on news.

Account